Clindamycin phosphate and Irbesartan drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Clindamycin phosphate and Irbesartan. Common interactions include deep vein thrombosis among females and chills among males.

The phase IV clinical study analyzes what interactions people who take Clindamycin phosphate and Irbesartan have. It is created by eHealthMe based on reports of 7 people who take Clindamycin phosphate and Irbesartan from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Nov, 26, 2022

7 people who take Clindamycin phosphate and Irbesartan together, and have interactions are studied.


What is Clindamycin phosphate?

Clindamycin phosphate has active ingredients of clindamycin phosphate. It is often used in infection. eHealthMe is studying from 3,458 Clindamycin phosphate users for its effectiveness, alternative drugs and more.

What is Irbesartan?

Irbesartan has active ingredients of irbesartan. It is often used in high blood pressure. eHealthMe is studying from 29,908 Irbesartan users for its effectiveness, alternative drugs and more.

Number of Clindamycin phosphate and Irbesartan reports submitted per year:

Clindamycin phosphate and Irbesartan drug interactions.

Common Clindamycin Phosphate and Irbesartan drug interactions by gender *:

female:

  1. Deep vein thrombosis
  2. Drug intolerance
  3. Fatigue
  4. Haemoglobin decreased
  5. Major depression
  6. Panic attack
  7. Rash
  8. Renal failure acute
  9. Seborrhoeic dermatitis
  10. Sluggishness

male:

  1. Chills
  2. Dermatitis exfoliative
  3. Erythema
  4. Skin exfoliation
  5. Skin fissures
  6. Tachycardia

Common Clindamycin Phosphate and Irbesartan drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Chills
  2. Dermatitis exfoliative
  3. Erythema
  4. Skin exfoliation
  5. Skin fissures
  6. Tachycardia

60+:

  1. Constipation
  2. Deep vein thrombosis

* Approximation only. Some reports may have incomplete information.

Do you take Clindamycin phosphate and Irbesartan?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Clindamycin phosphate and Irbesartan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Clindamycin phosphate side effects:

Browse all side effects of Clindamycin phosphate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Irbesartan side effects:

Browse all side effects of Irbesartan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Clindamycin phosphate interactions:

Browse all interactions between Clindamycin phosphate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Irbesartan interactions:

Browse all interactions between Irbesartan and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on clindamycin phosphate and irbesartan (the active ingredients of Clindamycin phosphate and Irbesartan, respectively), and Clindamycin phosphate and Irbesartan (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Clindamycin phosphate and Irbesartan.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: